31 results about "Neuronal precursor" patented technology

A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.

Disclosed are methods and materials for treatment of central nervous system lesions. Preferred methods and materials comprise neuronal precursor cells and / or marrow adherent stem cell-derived neuronal cells.

The present invention relates to VEGF-C or VEGF-D materials and methods for promoting growth and differentiation of neural stem cells, neuronal and neuronal precursor cells, oligodendrocytes and oligodendrocyte precursor cells and materials and methods for administering said cells to inhibit neuropathology.

Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor system can be manipulated positively or negatively to regulate mitosis in neuronal precursor cells. The ligand / receptor system involves PACAP, PACAP receptor, PAC1, and related antagonists. The methods of regulation of the present invention may model be used to define cell cycle regulation in the developing neurons. The present invention may also be used to control or cure diseases related to or caused by damage to or destruction of neuronal cells.

The invention discloses a method for differentiating human neural stem cells into dopaminergic neuron by in-vitro directional induction. The method comprises the following steps of adherent culture of human neural stem cells, induction of dopaminergic neuron precursor cells, directional induction of dopaminergic neuron and cryopreservation and anabiosis of the human neural stem cells and the dopaminergic neuron precursor cells. By virtue of the steps of the method disclosed by the invention, abundant dopaminergic neuron can be obtained in vitro; compared with the plurality of dopaminergic neuron production ways at present, the method disclosed by the invention has characteristics of low cost, high safety, high production efficiency and strong operability. The in-vitro dopaminergic neuron production way can provide a novel idea for applying dopaminergic neuron to clinical transplant treatment of the Parkinson disease.

An agent for promoting the proliferation or differentiation of a stem cell and / or neural progenitor cell, comprising a compound represented by Formula: wherein each of R<1 >and R<2 >is H, a hydrocarbon group or a heterocyclic group, or taken together with the adjacent carbon atom to form a ring, R<3 >is H, a hydrocarbon group or a heterocyclic group, W is a group represented by Formula: wherein Ring A is an optionally substituted benzene ring, Ring B is an optionally substituted 5- to 7-membered nitrogen-containing heterocyclic ring, R<4 >is an acyl group having an aliphatic hydrocarbon group, which is substituted by an aromatic group and may have a further substitutent, or aromatic group, R<5 >is H, C1-6 alkyl or acyl, R<4c >is an aromatic group, an aliphatic hydrocarbon group or acyl, and X is O or S; Y is O, S or NH, Ring C is an optionally substituted benzene ring, or a salt or prodrug thereof is provided.

A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.

The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and / or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject.

The present invention relates to VEGF-C or VEGF-D materials and methods for promoting growth and differentiation of neural stem cells, neuronal and neuronal precursor cells, oligodendrocytes and oligodendrocyte precursor cells and materials and methods for administering said cells to inhibit neuropathology.

The invention discloses a method for constructing brain-like tissue by using umbilical cord mesenchymal stem cells, which comprises the following steps: 1) carrying out stem cell culture on a human umbilical cord mesenchymal stem cell line to obtain subculture cells; 2) carrying out nerve induction differentiation on the subculture cells to obtain differentiated neuronal precursor cells which areembryoid-like nerve spheres; 3) carrying out induction culture on the embryoid-like nerve spheres to obtain a neural rosettte neural tube-like structure neural spheres; and (4) carrying out differentiation culture on the neural rosettte neural tube-like structure neural spheres to obtain a human brain-like organ which contains a plurality of types of neuron mixtures. The human mesenchymal stem cells are differentiated into various neurons for the first time, the brain-like tissue is constructed, the brain-like tissue can be used as a drug screening platform, and the application prospect is wide.

The invention provides a spinal neuron damage treating agent for use in the treatment of spinal neuron damage, or an agent for promoting the proliferation of spinal neuronal precursor cells in the culture of spinal neuronal precursor cells, or an agent for promoting the regeneration of spinal nerves after transplantation of cultured spinal neuronal precursor cells, and the like.The invention provides an agent that contains a substance (e.g., ghrelin) that acts on the growth hormone secretagogue-receptor as an active ingredient, the agent being a spinal neuron damage treating agent for use in the treatment of spinal neuron damage, or an agent for promoting the proliferation of cultured spinal neuronal precursor cells in the culture of spinal neuronal precursor cells, or an agent for promoting the regeneration of spinal nerves after transplantation of cultured spinal neuronal precursor cells, and the like.

A self-renewing restricted stem cell population has been identified in developing (embryonic day 13.5) spinal cords that can differentiate into multiple neuronal phenotypes, but cannot differentiate into glial phenotypes. This neuronal-restricted precursor (NRP) expresses highly polysialated or embryonic neural cell adhesion molecule (E-NCAM) and is morphologically distinct from neuroepithelial stem cells (NEP cells) and spinal glial progenitors derived from embryonic day 10.5 spinal cord. NRP cells self renew over multiple passages in the presence of fibroblast growth factor (FGF) and neurotrophin 3 (NT-3) and express a characteristic subset of neuronal epitopes. When cultured in the presence of RA and the absence of FGF, NRP cells differentiate into GABAergic, glutaminergic, and cholinergic immunoreactive neurons. NRP cells can also be generated from multipotent NEP cells cultured from embryonic day 10.5 neural tubes. Clonal analysis shows that E-NCAM immunoreactive NRP cells arise from an NEP progenitor cell that generates other restricted CNS precursors. The NEP-derived E-NCAM immunoreactive cells undergo self renewal in defined medium and differentiate into multiple neuronal phenotypes in mass and clonal culture. Thus, a direct lineal relationship exists between multipotential NEP cells and more restricted neuronal precursor cells present in vivo at embryonic day 13.5 in the spinal cord. Methods for treating neurological diseases are also disclosed.

The invention provides a spinal neuron damage treating agent for use in the treatment of spinal neuron damage, or an agent for promoting the proliferation of spinal neuronal precursor cells in the culture of spinal neuronal precursor cells, or an agent for promoting the regeneration of spinal nerves after transplantation of cultured spinal neuronal precursor cells, and the like. The invention provides an agent that contains a substance (e.g., ghrelin) that acts on the growth hormone secretagogue-receptor as an active ingredient, the agent being a spinal neuron damage treating agent for use in the treatment of spinal neuron damage, or an agent for promoting the proliferation of cultured spinal neuronal precursor cells in the culture of spinal neuronal precursor cells, or an agent for promoting the regeneration of spinal nerves after transplantation of cultured spinal neuronal precursor cells, and the like.

To treat epilepsy or schizophrenia by transplanting precursor cells of GABAergic neurons into a region where GABAergic neurons are lost or decreased in the brain of a patient suffering from the disease, it is intended to provide a method for separating a precursor cell of GABAergic neuron in an adult or a fetal nerve tissue or a precursor cell of GABAergic neuron derived from an embryo stem cell. The invention of this application comprises the step of preparing a cell population containing a precursor cell of GABAergic neuron, the step of introducing a DNA, in which a reporter gene emitting fluorescence detectable even in vivo is attached to the downstream of a promoter of GAD67 gene or GAD65 gene that is gene of an inhibitory neurotransmitter GABA synthase, into dispersed cells, the step of isolating a GABAergic neuron and a precursor cell of GABAergic neuron based on the presence / absence of the fluorescence from the reporter protein, and the step of isolating the precursor cell of GABAergic neuron based on the possession of proliferative capability.

The invention relates to preparation of neuronal precursor cells, compositions comprising same and therapeutic uses.

The invention discloses a method for differentiating human neural stem cells into dopaminergic neuron by in-vitro directional induction. The method comprises the following steps of adherent culture of human neural stem cells, induction of dopaminergic neuron precursor cells, directional induction of dopaminergic neuron and cryopreservation and anabiosis of the human neural stem cells and the dopaminergic neuron precursor cells. By virtue of the steps of the method disclosed by the invention, abundant dopaminergic neuron can be obtained in vitro; compared with the plurality of dopaminergic neuron production ways at present, the method disclosed by the invention has characteristics of low cost, high safety, high production efficiency and strong operability. The in-vitro dopaminergic neuron production way can provide a novel idea for applying dopaminergic neuron to clinical transplant treatment of the Parkinson disease.

A method for inducing differentiation of embryonic stem cells into neuronal precursors is provided as well as an assay for neuronal precursor or progenitor cells and a method for identifying agents that inhibit or reduce an increase in neurite degeneration.

The invention discloses an induction medium. The medium is employed to perform induction culture on a human-adipose derived adult stem cell to make the human-adipose derived adult stem cell differentiated into neuronal precursor cells, and comprises non-essential amino acid (NEAA), beta-mercaptoethanol, glutamine, a growth factor and a neurotrophic factor; the volume ratio of the NEAA to the beta-mercaptoethanol is (4:1)-(13:1); the volume ratio of the NEAA to the glutamine is (1:2)-(2:1); the growth factor consists of a basic fibroblast growth factor (bFGF) of 10-20 ng / mL and an epidermal growth factor (EGF) of 10-20 ng / mL; and the neurotrophic factor consists of a brain derived neurotrophic factor (BDNF) of 10-20 ng / mL, a nerve growth factor (NGF) of 10-20 ng / mL and neurotrophin-3 (NT3)of 10-20 ng / mL. A human-adipose derived adult stem cell-derived neuronal precursor cell population disclosed by the invention is obtained by inducing the human-adipose derived adult stem cells to be differentiated by the specific induction medium, and the neuronal precursor cells have a good health status and are high in activity and purity.

This patent application relates to a method for determining the in vitro efficacy profile of a drug candidate using standardized cell cultures of uniformly distributed differentiated neural cells (NCs) from at least two primate species, wherein the differentiated NC cultures are qualified for high throughput screening based on a dissociation and reseeding step performed on the differentiated NCs. The method includes differentiating human and / or non-human primate neuronal precursor cells (NPCs) to neuronal cells (NCs) followed by dissociating the differentiated NCs from its support and reseeding the differentiated NCs in a high-throughput cell culture format resulting in robust cultures suitable for high-throughput drug screening assays, in particular to screen antisense oligonucleotides.

The invention discloses neuron precursor cells derived from adipose-derived stem cells, and a preparation method and application of the neuron precursor cells in treating central nervous system injury. The method for differentiating the adipose-derived stem cells into the neuronal precursor cells comprises the following steps: S1, adding the adipose-derived stem cells into a neuronal culture medium containing an inducer, and carrying out induction culture for 24 hours; and S2, adding neurotrophic factors into the neuron culture medium in the S1, and performing culturing for 24-72 hours. A neuron precursor cell population derived from adipose-derived stem cells is obtained by inducing and differentiating the adipose-derived stem cells through the specific inducer, and the neuronal precursorcells are good in health condition and high in activity and purity.

The present disclosure relates to novel multi-organ-chips establishing the differentiation of induced pluripotent stem cell (iPSC)-derived cells into organ equivalents on microfluidic devices and corresponding methods of generating organ equivalents. The present disclosure also relates to novel bioengineered tissue constructs mimicking organ barriers generated with iPSC-derived endothelial cells and / or organoids bioprinted in, and / or seeded on, a hydrogel. The present disclosure further relates to methods of bio-engineering organ constructs comprising co-culturing iPSC-derived organ precursor cells and iPSC-derived fibroblasts and endothelial cells. The present disclosure specifically provides a microfluidic device comprising: (i) iPSC-derived hepatocyte precursor cells; (ii) iPSC-derived intestinal precursor cells; (iii) iPSC-derived renal tubular precursor cells; and (iv) iPSC-derived neuronal precursor cells; wherein the iPSC-derived precursor cells according to (i), (ii), (iii) and (iv) are differentiated from a single donor iPSC reprogrammed from a single type of somatic cell.

The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and / or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject.

The invention discloses a method for constructing brain-like tissue using umbilical cord mesenchymal stem cells, which comprises the following steps: 1) performing stem cell culture on a human umbilical cord mesenchymal stem cell line to obtain subcultured cells; 2) subcultured cells Inducing neural differentiation to obtain differentiated neuron precursor cells, which are embryoid body-like neurospheres; 3) Inducing and culturing embryoid body-like neurospheres to obtain neural rosette neural tube-like neurospheres; 4) neural The rosette neural tube-like structure neurospheres were differentiated and cultured to obtain human brain organoids, which contain a mixture of various types of neurons. The present invention differentiates human mesenchymal stem cells into various neurons for the first time and constructs brain-like tissue, which can be used as a drug screening platform and has broad application prospects.